Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 7/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL201045 | 0.86 | LMNA (0.50) | KMT2ALMNACNR1CNR2TSHR | |
| SCHEMBL199907 | 0.85 | LMNA (0.49) | KMT2ALMNACNR1CNR2TSHR | |
| Hydrochloric Acid SCHEMBL199908 | 0.85 | LMNA (0.49) | KMT2ALMNACNR1CNR2TSHR | |
| SCHEMBL524841 | 0.80 | POLB (0.51) | LMNACNR1CNR2TSHRSMN1; SMN2 | |
| SCHEMBL16326512 | 0.80 | KDM4E (0.45) | KMT2ACNR1CNR2RAB9A | |
| SCHEMBL2737128 | 0.79 | TSHR (0.51) | KMT2ALMNATSHRSMN1; SMN2RAB9A | |
| SCHEMBL2826311 | 0.78 | MAP4K4 (0.50) | KMT2ACNR1CNR2LIPE | |
| SCHEMBL13610689 | 0.78 | CYP4F2 (0.39) | CNR1CNR2 | |
| SCHEMBL6634752 | 0.78 | KMT2A (0.57) | KMT2ALMNARAB9AMRGPRX4LIPE | |
| SCHEMBL3476037 | 0.76 | MAP4K4 (0.45) | KMT2ALMNACNR1CNR2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041893-A1 | FORMATION OF TETRA-SUBSTITUTED ENAMIDES AND STEREOSELECTIVE REDUCTION THEREOF | MERCK SHARP & DOHME CORP. | 2010-02-18 | — | — | US | disclosed |
| US-20100041893-A1 | FORMATION OF TETRA-SUBSTITUTED ENAMIDES AND STEREOSELECTIVE REDUCTION THEREOF | MERCK SHARP & DOHME CORP. | 2010-02-18 | — | — | US | disclosed |
| US-20100041893-A1 | FORMATION OF TETRA-SUBSTITUTED ENAMIDES AND STEREOSELECTIVE REDUCTION THEREOF | MERCK SHARP & DOHME CORP. | 2010-02-18 | — | — | US | disclosed |
| US-20090306037-A1 | Combination of a Dipeptidyl Peptidase-IV Inhibitor and a Cannabinoid CB1 Receptor Antagonist for the Treatment of Diabetes and Obesity | MERCK & CO., INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306037-A1 | Combination of a Dipeptidyl Peptidase-IV Inhibitor and a Cannabinoid CB1 Receptor Antagonist for the Treatment of Diabetes and Obesity | MERCK & CO., INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306037-A1 | Combination of a Dipeptidyl Peptidase-IV Inhibitor and a Cannabinoid CB1 Receptor Antagonist for the Treatment of Diabetes and Obesity | MERCK & CO., INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-7629470-B2 | Formation of tetra-substituted enamides and stereoselective reduction thereof | MERCK & CO., INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629470-B2 | Formation of tetra-substituted enamides and stereoselective reduction thereof | MERCK & CO., INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629470-B2 | Formation of tetra-substituted enamides and stereoselective reduction thereof | MERCK & CO., INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-7595417-B2 | Cyanation of aromatic halides | MERCK & CO., INC. (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1496838-A4 | SUBSTITUTED AMIDES | MERCK & CO INC (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1765771-A4 | FORMATION OF TETRA-SUBSTITUTED ENAMIDES AND STEREOSELECTIVE REDUCTION THEREOF | MERCK & CO INC (US) | 2008-04-02 | — | — | EP | disclosed |
| EP-1879582-A2 | COMBINATION OF DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND A CANNABINOID CB1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF DIABETES AND OBESITY | Merck & Co., Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1765771-A2 | FORMATION OF TETRA-SUBSTITUTED ENAMIDES AND STEREOSELECTIVE REDUCTION THEREOF | Merck & Co., Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006119260-A2 | COMBINATION OF DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND A CANNABINOID CB1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF DIABETES AND OBESITY | MERCK & CO., INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006119260-A2 | COMBINATION OF DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND A CANNABINOID CB1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF DIABETES AND OBESITY | MERCK & CO., INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| US-20060106223-A1 | Cyanation of aromatic halides | MERCK SHARP & DOHME CORP. | 2006-05-18 | — | — | US | disclosed |
| WO-2006017045-A2 | FORMATION OF TETRA-SUBSTITUTED ENAMIDES AND STEREOSELECTIVE REDUCTION THEREOF | MERCK & CO., INC. (US) | 2006-02-16 | — | — | WO | disclosed |
| EP-1496838-A2 | SUBSTITUTED AMIDES | Merck & Co., Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003077847-A2 | SUBSTITUTED AMIDES | MERCK & CO., INC. (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106223-A1 | Cyanation of aromatic halides | NEK6, HCN4, NPM1 | KMT2A 629/4885LMNA 1858/4885CNR1 458/4885 |
| US-20090306037-A1 | Combination of a Dipeptidyl Peptidase-IV Inhibitor and a Cannabinoid CB1 Receptor Antagonist for the Treatment of Diabetes and Obesity | DPP4, DPP3, DPP7 | KMT2A 2566/4885LMNA 4483/4885CNR1 6/4885 |
| US-20100041893-A1 | FORMATION OF TETRA-SUBSTITUTED ENAMIDES AND STEREOSELECTIVE REDUCTION THEREOF | ENY2, INF2, ECI1 | KMT2A 1046/4885LMNA 2348/4885CNR1 2041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.